Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Buy at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a strong-buy rating to a buy rating in a research note published on Sunday morning.

Other equities research analysts also recently issued reports about the stock. Chardan Capital lifted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. UBS Group lifted their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research report on Friday, August 1st. Truist Financial lifted their price objective on Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Barclays boosted their price objective on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $478.67.

Get Our Latest Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Trading Down 2.4%

NASDAQ:ALNY opened at $423.47 on Friday. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $495.55. The firm has a fifty day simple moving average of $459.45 and a 200-day simple moving average of $373.65. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a market capitalization of $55.51 billion, a P/E ratio of -171.45 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping the consensus estimate of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $943.37 million. During the same period in the previous year, the firm posted ($0.50) earnings per share. The business’s revenue for the quarter was up 149.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares of the company’s stock, valued at approximately $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company’s stock, valued at $362,390. The trade was a 95.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 98,144 shares of company stock valued at $44,160,261 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Norges Bank purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at $662,837,000. Holocene Advisors LP purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at $194,616,000. Orbis Allan Gray Ltd increased its stake in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $162,577,000. Finally, Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles